Literature DB >> 24521680

Localized ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiation therapy: a long-term outcome in 86 patients with 104 treated eyes.

Ken Harada1, Naoya Murakami2, Mayuka Kitaguchi2, Shuhei Sekii2, Kana Takahashi2, Kotaro Yoshio2, Koji Inaba2, Madoka Morota2, Yoshinori Ito2, Minako Sumi2, Shigenobu Suzuki3, Kensei Tobinai4, Takashi Uno5, Jun Itami2.   

Abstract

PURPOSE: To evaluate the natural history, behavior of progression, prognostic factors, and treatment-related adverse effects of primary ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphoma (POAML). METHODS AND MATERIALS: Eighty-six patients with histologically proven stage I POAML treated with radiation therapy at National Cancer Center Hospital, Tokyo between 1990 and 2010 were retrospectively reviewed. The median age was 56 years (range, 18-85 years). The median dose administered was 30 Gy (range, 30-46 Gy). Seventy-seven patients (90%) were treated by radiation therapy alone.
RESULTS: The median follow-up duration was 9 years (range, 0.9-22 years). The 5- and 10-year overall survival (OS) rates were 97.6% and 93.5%, respectively, and no patients died of lymphoma. Patients with tumor sizes ≥4 cm showed a greater risk of contralateral relapse (P=.012). Six patients with contralateral relapse were seen and treated by radiation therapy alone, and all the lesions were controlled well, with follow-up times of 3 to 12 years. There was 1 case of local relapse after radiation therapy alone, and 3 cases of relapse occurred in a distant site. Cataracts developed in 36 of the 65 eyes treated without lens shielding and in 12 of the 39 patients with lens shielding (P=.037).
CONCLUSIONS: The majority of patients with POAML showed behavior consistent with that of localized, indolent diseases. Thirty gray of local irradiation seems to be quite effective. The initial bilateral involvement and contralateral orbital relapses can be also controlled with radiation therapy alone. Lens shielding reduces the risk of cataract.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24521680     DOI: 10.1016/j.ijrobp.2013.11.235

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  20 in total

1.  Treatment-associated outcomes of patients with primary ocular adnexal MALT lymphoma after accurate diagnosis.

Authors:  Yuya Masuda; Kazuto Takeuchi; Toshio Kodama; Tomoaki Fujisaki; Yoshitaka Imaizumi; Eiichi Otsuka; Shuji Ozaki; Shinji Hasebe; Yoshihiro Yakushijin
Journal:  Int J Clin Oncol       Date:  2019-06-06       Impact factor: 3.402

2.  Conjunctival lymphoma.

Authors:  Jenny Jing Li; Weina Chen; Navid Sadeghi
Journal:  BMJ Case Rep       Date:  2019-07-10

3.  Clinical features and treatment outcomes of primary ocular adnexal mucosa-associated lymphoid tissue lymphoma: a single center retrospective analysis of 64 patients in China.

Authors:  Hui Yu; Yu-Xin Du; Zhen-Chang Sun; Xiao-Rui Fu; Nan Tan; Wei-Feng Gong; Ming-Zhi Zhang
Journal:  Int J Ophthalmol       Date:  2019-11-18       Impact factor: 1.779

4.  Diagnostic bone marrow biopsy in patients with stage I EMZL treated with radiation therapy: needed or not?

Authors:  Juan Pablo Alderuccio; Derek Isrow; Isildinha M Reis; Sunil Girish Iyer; Jessica J Meshman; Wei Zhao; Francisco Vega; Jennifer R Chapman; Arnold M Markoe; Izidore S Lossos
Journal:  Blood       Date:  2020-04-09       Impact factor: 22.113

5.  Methotrexate-associated orbital lymphoproliferative disorder in a patient with rheumatoid arthritis: a case report.

Authors:  Yuka Kobayashi; Kazuhiro Kimura; Youichiro Fujitsu; Kuniisa Shinkawa; Hiroko Muta; Koh-Hei Sonoda
Journal:  Jpn J Ophthalmol       Date:  2016-03-28       Impact factor: 2.447

6.  Radical surgery may be not an optimal treatment approach for pulmonary MALT lymphoma.

Authors:  Liang Wang; Zhong-Jun Xia; Yu-Jing Zhang; Hui-Qiang Huang; Tong-Yu Lin; Yue Lu
Journal:  Tumour Biol       Date:  2015-03-24

7.  Clinicopathologic Characteristics Associated with Prognosis in Ocular Extranodal Marginal Zone B Cell Lymphoma.

Authors:  Soyeon Choi; Minjung Seo; Seol Hoon Park; Jae-Cheol Jo; Seoung Wan Chae; Ju-Hyang Lee; Hee Jeong Cha
Journal:  Medicina (Kaunas)       Date:  2022-06-17       Impact factor: 2.948

8.  Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma.

Authors:  S Teckie; S Qi; M Chelius; S Lovie; M Hsu; A Noy; C Portlock; J Yahalom
Journal:  Ann Oncol       Date:  2017-05-01       Impact factor: 32.976

Review 9.  The role of infectious agents, antibiotics, and antiviral therapy in the treatment of extranodal marginal zone lymphoma and other low-grade lymphomas.

Authors:  Laahn H Foster; Craig A Portell
Journal:  Curr Treat Options Oncol       Date:  2015-06

10.  Extranodal Marginal Zone Lymphoma of Ocular Adnexa: Outcomes following Radiation Therapy.

Authors:  Sean Platt; Yahya Al Zahrani; Nakul Singh; Brian Hill; Sheen Cherian; Arun D Singh
Journal:  Ocul Oncol Pathol       Date:  2017-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.